higher chloride crystalloid
OtherNormal saline (chloride concentration 154 mmol/L)
NCT Number: NCT03677102
Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new and direct randomized controlled trial (RCT) evidence. Editorials published in leading critical care journals have called for RCT's to address this important clinical question. This trial will directly compare low chloride versus normal chloride for resuscitation in septic shock on patient-important outcomes such as mortality and AKI.
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Phase 2 / Phase 3
University of Calgary - Foothills Medical Centre, Calgary, Alberta, Canada
Severe infection can lead to many complications within the human body including low blood pressure, which is called septic shock. The main treatments for septic shock are intravenous antibiotics and intravenous fluid.
There are many different intravenous fluids available for doctors to use. Each one of these fluids has potential advantages as well as potential disadvantages. Doctors will often look at many things when deciding which fluid to give including the results of bloodwork and the clinical characteristics of the patients themselves. There is limited direction from research studies that using one fluid type is better than another. Some preliminary research in the field has suggested that one specific electrolyte, call chloride, may be harmful when given to patients in high concentrations. Animal research has shown that the administration of high chloride fluids may be harmful to the lungs, kidneys, gastrointestinal and muscle cells. Some intravenous fluids have higher concentrations of chloride than others.
The investigators plan to study the impact of giving patients with severe infection intravenous fluids with either a high chloride concentration (normal saline or high chloride albumin) or a low chloride concentration (Ringers Lactate or low chloride albumin). This trial will build on the earlier pilot, phase 1 study and will look at patient-important outcomes such as rate of death, kidney failure and length of stay in the ICU. This larger study has the potential to guide the care of critically ill patients with infection worldwide.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Normal saline (chloride concentration 154 mmol/L)
Ringer's Lactate (chloride concentration 110 mmol/L)
Time frame: up to 30 days
Investigators expect that if a difference in survival is demonstrated that this will be evident within 30 days.
Time frame: up to 30 days
Investigators expect that if a difference in survival is demonstrated, that this will be evident within 30 days.
Time frame: up to 30 days
Investigators expect that if a difference in survival is demonstrated, that this will be evident within 30 days.
Time frame: up to 30 days
length of hospital stay up to 30 days
Time frame: up to 30 days
length of ICU stay up to 30 days
Time frame: up to 30 days
Acute kidney injury - development of stage 2 or worse acute kidney injury (AKI) according to KDIGO guidelines17 based strictly on serum creatinine criteria. Stage 2 AKI is defined as serum creatinine 2.0-2.9 times baseline. For the purposes of analysis, baseline creatinine will be an outpatient reading within 365 days of the current admission date. If multiple pre-hospitalization values are available, the value closest to the date of hospital admission will be used. If an outpatient pre-hospitalization value is not available, the lowest creatinine value obtained during the current hospitalization will be considered baseline 18.
Time frame: up to 30 days
defined as cumulative number of days alive without receiving greater than or equal to 2 hours of mechanical ventilation, censored at 30 days; patients who die prior to 30 days will be assigned -1
Time frame: up to 30 days
defined as the cumulative number of days alive without requiring greater than or equal to 2 hours of intravenous vasopressor support, censored at 30 days; patients who die prior to 30 days will be assigned -1
Time frame: up to 30 days
calculated using the SOFA score (sequential organ failure assessments score) , defined as the net change in SOFA from day 1 until ICU discharge or death minimum 0, maximum 24 higher score is worse
Time frame: up to 30 days
the number of patients with hyperchloremia
Time frame: up to 30 days
the number of patients with hyperkalemia
Time frame: up to 30 days
the number of patients with hypernatremia
Time frame: up to 30 days
the number of patients with acidosis
Time frame: up to 30 days
critically ill patients are admitted to the ICU for life-sustaining therapies and medical complications are likely to occur in this population consistent with severity of illness. Due to these unique morbidity and mortality expectations, we don't collect generic adverse events but instead focus on study-related SAEs that the attending physician believes related to the study fluid with plausible time sequence and biological plausibility
McMaster University
Other
Fluids in Septic Shock (FISSH): a Randomized Controlled Trial
Acronym: FISSH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04130230
Infections, Inflammation
Tanta, EL-Gharbia, Egypt
View Trial DetailsNCT00525369
Infections, Inflammation
Berlin, State of Berlin, Germany
View Trial DetailsNCT07425587
Disease Attributes, Emergencies
Gainesville, Florida, United States
View Trial DetailsNCT06654895
Infections, Inflammation
Gainesville, Florida, United States
View Trial Details